Azurity Pharmaceuticals
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).
Inclusion Criteria: * Pediatric participants (ages 1 month to 17 years of age, inclusive) will be considered eligible for the study based on the following criteria: 1. Voluntarily obtained informed consent from parent/legal guardian of the participant and assent from the participant, when appropriate. 2. Willing and able to follow protocol specific requirements. 3. Participant of 1 month to 17 years of age, inclusive (at time of consent). 4. Participant diagnosed with partial-onset (focal) seizures, with or without secondary generalization as per current International League Against…
Zonisamide oral suspension
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.